Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Godavari Drugs's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Godavari Drugs's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Godavari Drugs Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Godavari Drugs's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Godavari Drugs's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Godavari Drugs (BOM:530317) has a Buyback Yield % of 0.00 as of Aug. 25, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Godavari Drugs and its competitors. According to the industry distribution chart, Godavari Drugs ranks #175 out of 245 companies in the Drug Manufacturers industry, placing it in the top 71.4%.
Is Godavari Drugs' Buyback Yield % too high?
Godavari Drugs' current Buyback Yield % is 0.00. Based on the distribution chart, Godavari Drugs ranks #175 out of 245 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Godavari Drugs has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Godavari Drugs' Buyback Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Godavari Drugs ranks #175 out of 245 companies for Buyback Yield %. This places Godavari Drugs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Godavari Drugs and its competitors. Godavari Drugs's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Godavari Drugs stock overvalued right now?
Based on GuruFocus' analysis, Godavari Drugs (BOM:530317) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹75.69, compared to a current price of ₹97.00 — trading 28.2% above its estimated fair value. The current Buyback Yield % is 0.00. Godavari Drugs' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Godavari Drugs (BOM:530317), the current Buyback Yield % is 0.00 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Godavari Drugs (BOM:530317) Overvalued in 2026?
Based on GuruFocus' analysis, Godavari Drugs stock appears to be overvalued.
The current stock price of ₹97.00 is trading 28.2% above its estimated GF Value™ of ₹75.69.
GuruFocus considers Godavari Drugs to be Modestly Overvalued.
Key valuation signals for BOM:530317:
Buyback Yield %: 0.00
GF Value™: ₹75.69 vs. price of ₹97.00 (28.2% above fair value)
No single metric tells the full story. See the BOM:530317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Godavari Drugs Ltd is an India-based pharmaceutical company. It is principally engaged in manufacturing of APl's, intermediates and fine chemicals,. The firm's product includes Ciprofloxacin hydrochloride, ciprofloxacin, ciprofloxacin lactate, ciprofloxacin lactate, and Others. The company operates only one segment which is the manufacture and sale of Active Pharmaceutical Ingredients (API) and its intermediates.
60GF Score
Get the complete analysis for BOM:530317
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530317 has been successfully added to your 
